Sensitivity analysis | Sample size | Difference [not-susceptible–susceptible] (P-value) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Probability of progressing to cUTI | All-cause costs | UTI-related costs | All-cause costs (winsorized) | UTI-related costs (winsorized) | |||||||
Difference | P-value | Difference | P-value | Difference | P-value | Difference | P-value | Difference | P-value | ||
Baseline | 1009 |  + 0.060 |  < 0.001* |  + 430.9 | 0.125 |  + 184.3 | 0.144 |  + 425.7 | 0.031* |  + 156.8 | 0.034* |
#1 (strict exclusion) | 661 |  + 0.039 | 0.009* |  + 797.7 | 0.014* |  + 304.6 | 0.043* |  + 653.5 | 0.002* |  + 217.5 | 0.028* |
#2 (loose exclusion) | 1009 |  + 0.060 |  < 0.001* |  + 430.9 | 0.125 |  + 184.3 | 0.144 |  + 425.7 | 0.031* |  + 156.8 | 0.034* |
#3 (30-day follow-up) | 1200 |  + 0.057 |  < 0.001* | − 12.85 | 0.910 |  + 17.57 | 0.877 |  + 36.00 | 0.614 |  + 22.65 | 0.555 |
#4 (360-day follow-up) | 834 |  + 0.058 |  < 0.001* |  + 412.2 | 0.285 |  + 126.7 | 0.409 |  + 301.9 | 0.256 |  + 65.25 | 0.478 |
#5 (infectious disease exclusion) | 955 |  + 0.058 |  < 0.001* |  + 511.7 | 0.060 |  + 206.5 | 0.085 |  + 471.7 | 0.012* |  + 73.15 | 0.139 |
#6 (FQ-only) | 166 |  + 0.036 | 0.387 |  + 605.8 | 0.316 |  + 186.3 | 0.471 |  + 484.9 | 0.307 |  + 196.0 | 0.369 |